Mediaboss Marketing

EMA has published recommendations for industry on good practices to ensure continuity in the supply of human medicines, prevent shortages and reduce their impact .

Medicine shortages are a global health problem and are increasingly affecting European countries. Shortages can lead to medicine rationing and delay in critical treatments, with a significant impact on patient care. In addition, patients may need to use less effective alternatives and face an increased risk of medication errors. Ensuring the availability of authorised medicines in the European Union (EU) is a key priority for EMA and the European medicines regulatory network.

The guidance describes the various stakeholders involved in the medicine supply chain and their responsibilities and role in the prevention and management of medicine shortages. It provides ten recommendations for marketing authorisation holders, wholesalers, distributors and manufacturers to minimise the occurrence of medicine shortages and their impact. The recommendations include:

The recommendations are based on the analysis of causes of shortages and regulators first-hand experience in coordinating the management of shortages, and industry associations have been consulted.

The guidance has been developed by the HMA / EMA Task Force on the Availability of Authorised Medicines for Human and Veterinary Use, a joint working group established by EMA and the Heads of Medicines Agencies (HMA) focusing on the availability of authorised medicines, and was presented at a multi-stakeholder workshop on shortages held on 1 and 2 March 2023.

It complements the guidance for patients and healthcare professionals organisations published last year to help prevent and manage shortages of human medicines.

More here:
Guidance for industry to prevent and mitigate medicine shortages ... - European Medicines Agency |